help button home button Am J Pathol ASIP WHAT IS IT?
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Order Full text via Infotrieve
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tipping, P. G.
Right arrow Articles by Wojta, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tipping, P. G.
Right arrow Articles by Wojta, J.

American Journal of Pathology, Vol 143, 875-885, Copyright © 1993 by American Society for Investigative Pathology


REGULAR ARTICLES

Atheromatous plaque macrophages produce plasminogen activator inhibitor type-1 and stimulate its production by endothelial cells and vascular smooth muscle cells

PG Tipping, P Davenport, M Gallicchio, EL Filonzi, J Apostolopoulos and J Wojta
Department of Medicine (Monash Medical Centre), Monash University, Clayton, Victoria, Australia.

The capacity of macrophages to influence directly and indirectly fibrinolytic processes in atherosclerosis was studied using macrophages isolated from atherosclerotic plaques of patients undergoing surgical repair of distal aortic and femoral arteries. These cells were characterized by their morphology, adherence, esterase positivity, and expression of CD14 antigen. Production of plasminogen activator inhibitor type-1 (PAI-1) by plaque macrophages (6.7 +/- 2.7 ng/10(5) cells/24 hours [mean +/- SEM]) was significantly greater than PAI-1 production by blood monocytes isolated simultaneously from the same patients (1.8 +/- 1.5 ng/10(5) cells/24 hours). Production of tissue type plasminogen activator and urokinase type was not augmented compared to blood monocytes. Conditioned medium from cultured plaque macrophages significantly increased production of PAI-1 by endothelial cells (85 +/- 11% above basal) and vascular smooth muscle cells (25 +/- 10%) in vitro. This response was significantly greater than the response to monocyte-conditioned medium (endothelial cells 38 +/- 11%, vascular smooth muscle cells 2.5 +/- 2.0%). Stimulation of endothelial cell PAI-1 production by macrophage-conditioned medium was partially inhibitable by a monoclonal antibody to transforming growth factor- beta. Tissue type plasminogen activator production by endothelial cells and vascular smooth muscle cells was not affected by plaque macrophage- or monocyte-conditioned medium. Urokinase type plasminogen activator production by endothelial cells and vascular smooth muscle cells was undetectable in control medium and was augmented to similar levels in response to plaque macrophage- and monocyte-conditioned media. These results demonstrate upregulation of PAI-1 production by macrophages in atheromatous plaques and the capacity of soluble products from plaque macrophages to upregulate PAI-1 production by endothelial cells and vascular smooth muscle cells in vitro. These data suggest that macrophages in atherosclerotic plaques may inhibit thrombolysis both directly and indirectly by effects of their soluble products on endothelial cells and vascular smooth muscle cells.


This article has been cited by other articles:


Home page
Cardiovasc ResHome page
E. M. Kairuz, M. N. Barber, C. R. Anderson, M. Kanagasundaram, G. R. Drummond, and R. L. Woods
C-type natriuretic peptide (CNP) suppresses plasminogen activator inhibitor-1 (PAI-1) in vivo
Cardiovasc Res, June 1, 2005; 66(3): 574 - 582.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Brogren, L. Karlsson, M. Andersson, L. Wang, D. Erlinge, and S. Jern
Platelets synthesize large amounts of active plasminogen activator inhibitor 1
Blood, December 15, 2004; 104(13): 3943 - 3948.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
W. A. Hsueh and D. Bruemmer
Peroxisome Proliferator-Activated Receptor {gamma}: Implications for Cardiovascular Disease
Hypertension, February 1, 2004; 43(2): 297 - 305.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
V. A. Ploplis, I. Cornelissen, M. J. Sandoval-Cooper, L. Weeks, F. A. Noria, and F. J. Castellino
Remodeling of the Vessel Wall after Copper-Induced Injury Is Highly Attenuated in Mice with a Total Deficiency of Plasminogen Activator Inhibitor-1
Am. J. Pathol., January 1, 2001; 158(1): 107 - 117.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
E. W. RAINES, H. KOYAMA, and N. O. CARRAGHER
The Extracellular Matrix Dynamically Regulates Smooth Muscle Cell Responsiveness to PDGF
Ann. N.Y. Acad. Sci., May 1, 2000; 902(1): 39 - 52.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Lopez, F. Peiretti, B. Bonardo, I. Juhan-Vague, and G. Nalbone
Tumor Necrosis Factor alpha Up-regulates in an Autocrine Manner the Synthesis of Plasminogen Activator Inhibitor Type-1 during Induction of Monocytic Differentiation of Human HL-60 Leukemia Cells
J. Biol. Chem., February 4, 2000; 275(5): 3081 - 3087.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. E. Sobel
Increased Plasminogen Activator Inhibitor-1 and Vasculopathy : A Reconcilable Paradox
Circulation, May 18, 1999; 99(19): 2496 - 2498.
[Full Text] [PDF]


Home page
CirculationHome page
A. M. Thogersen, J.-H. Jansson, K. Boman, T. K. Nilsson, L. Weinehall, F. Huhtasaari, and G. Hallmans
High Plasminogen Activator Inhibitor and Tissue Plasminogen Activator Levels in Plasma Precede a First Acute Myocardial Infarction in Both Men and Women : Evidence for the Fibrinolytic System as an Independent Primary Risk Factor
Circulation, November 24, 1998; 98(21): 2241 - 2247.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Geppert, S. Graf, R. Beckmann, S. Hornykewycz, E. Schuster, B. R. Binder, and K. Huber
Concentration of Endogenous tPA Antigen in Coronary Artery Disease : Relation to Thrombotic Events, Aspirin Treatment, Hyperlipidemia, and Multivessel Disease
Arterioscler. Thromb. Vasc. Biol., October 1, 1998; 18(10): 1634 - 1642.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. Kauhanen, V. Siren, O. Carpen, A. Vaheri, M. Lepantalo, and R. Lassila
Plasminogen Activator Inhibitor-1 in Neointima of Vein Grafts : Its Role in Reduced Fibrinolytic Potential and Graft Failure
Circulation, September 16, 1997; 96(6): 1783 - 1789.
[Abstract] [Full Text]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
G. Christ, P. Hufnagl, C. Kaun, G. Mundigler, G. Laufer, K. Huber, J. Wojta, and B. R. Binder
Antifibrinolytic Properties of the Vascular Wall: Dependence on the History of Smooth Muscle Cell Doublings In Vitro and In Vivo
Arterioscler. Thromb. Vasc. Biol., April 1, 1997; 17(4): 723 - 730.
[Abstract] [Full Text]


Home page
Circ. Res.Home page
S. M. Schwartz, D. deBlois, and E. R. M. O'Brien
The Intima : Soil for Atherosclerosis and Restenosis
Circ. Res., September 1, 1995; 77(3): 445 - 465.
[Full Text]


Home page
J. Biol. Chem.Home page
W.-Y. Zhang, I. Ishii, and H. S. Kruth
Plasmin-mediated Macrophage Reversal of Low Density Lipoprotein Aggregation
J. Biol. Chem., October 13, 2000; 275(42): 33176 - 33183.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the American Society for Investigative Pathology.